收藏切换
Efficacy and safety of anlotinib combined with toripalimab in the treatment of advanced non-small cell lung cancer with driver genes negative
收藏切换
Yuwei LIU, Wei YANG, Xiaohua GOU*, Shining JIAN, Lizhu LUO
World Clinical Drug | 2026, 47(5) : 495 - 501
Less
收藏切换
World Clinical Drug | 2026, 47(5): 495-501
• Article •
Efficacy and safety of anlotinib combined with toripalimab in the treatment of advanced non-small cell lung cancer with driver genes negative
Full
Yuwei LIU, Wei YANG, Xiaohua GOU*, Shining JIAN, Lizhu LUO
Affiliations
  • Department of Respiratory and Critical Care Medicine, First Central Hospital of Baoding, Baoding, Baoding 071000, Hebei Province, China
Published: 2026-05-10 doi: 10.13683/j.wph.2026.05.006
Outline
收藏切换
Objective

To explore the impact of anlotinib combined with toripalimab on the therapeutic efficacy and safety of patients with advanced non-small cell lung cancer(NSCLC).

Methods

A total of 88 patients with advanced NSCLC admitted to our hospital from March 2023 to June 2025 were selected. They were divided into the conventional group(anlotinib) and the combined group(anlotinib+teprotumumab) according to different treatment regimens. The objective response rate(ORR) and disease control rate(DCR) were compared between the two groups. The levels of serum indicators, tumor markers, quality of life and safety were evaluated between the two groups.

Results

The ORR and DCR in the combined group(38.30% and 87.24%) were both higher than those of the conventional group(17.07% and 68.29%, P<0.05). Compared to before treatment, the levels of serum indicators and tumor markers in both groups were lower(P<0.05), and the combined groups was obviously lower than the conventional group(P<0.05). The scores of the functional assessment of cancer therapy-lung cancer(FACT-L) scale of the two groups increased compared to before, and the scores of the Patient Health Questionnaire-9(PHQ-9) decreased(P<0.05). Moreover, the FACT-L score of the combined group was higher than that of the conventional group, and the PHQ-9 score was lower than that of the conventional group(P<0.05). There was no significantly difference in the incidence of adverse reactions between the two groups(P>0.05).

Conclusion

The combination therapy of anlotinib and toripalimab can significantly reduce the levels of serum tumor markers in patients with advanced NSCLC, improve their quality of life, and has remarkable efficacy.Moreover, it demonstrates good safety.

anlotinib  /  toripalimab  /  advanced non-small cell lung cancer  /  safety
刘宇伟, 杨卫, 勾小华, 监士宁, 骆丽珠. 安罗替尼与特瑞普利单抗联合治疗驱动基因阴性晚期非小细胞肺癌的疗效及安全性分析. 世界临床药物, 2026 , 47 (5) : 495 -501 . DOI: 10.13683/j.wph.2026.05.006
Yuwei LIU, Wei YANG, Xiaohua GOU, Shining JIAN, Lizhu LUO. Efficacy and safety of anlotinib combined with toripalimab in the treatment of advanced non-small cell lung cancer with driver genes negative[J]. World Clinical Drug, 2026 , 47 (5) : 495 -501 . DOI: 10.13683/j.wph.2026.05.006
Year 2026 volume 47 Issue 5
56
13
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.05.006
  • Receive Date:2025-12-22
  • Online Date:2026-11-05
  • Published:2026-05-10
Article Data
Affiliations
History
  • Received:2025-12-22
Affiliations
    Department of Respiratory and Critical Care Medicine, First Central Hospital of Baoding, Baoding, Baoding 071000, Hebei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.05.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT